Revenue Insights: Vertex Pharmaceuticals Incorporated and Xencor, Inc. Performance Compared

Vertex vs. Xencor: A Decade of Revenue Growth

__timestampVertex Pharmaceuticals IncorporatedXencor, Inc.
Wednesday, January 1, 20145804150009520000
Thursday, January 1, 2015103233600027762000
Friday, January 1, 2016170217700087520000
Sunday, January 1, 2017248865200035711000
Monday, January 1, 2018304759700040603000
Tuesday, January 1, 20194162821000156700000
Wednesday, January 1, 20206205683000122694000
Friday, January 1, 20217574400000275111000
Saturday, January 1, 20228930700000164579000
Sunday, January 1, 20239869200000168338000
Monday, January 1, 202411020100000
Loading chart...

Data in motion

Revenue Growth: Vertex Pharmaceuticals vs. Xencor

In the competitive landscape of biotechnology, Vertex Pharmaceuticals Incorporated and Xencor, Inc. have showcased contrasting revenue trajectories over the past decade. Since 2014, Vertex has demonstrated a remarkable growth, with its revenue surging by over 1,600%, reaching nearly $9.9 billion by 2023. This growth underscores Vertex's strategic advancements in the pharmaceutical sector, particularly in the development of innovative therapies.

Conversely, Xencor, Inc., while experiencing a more modest growth, has seen its revenue increase by approximately 1,670% over the same period, peaking at $275 million in 2021. Despite the smaller scale, Xencor's focus on antibody and cytokine therapeutics has positioned it as a promising player in the biotech industry.

This comparison highlights the diverse strategies and market positions of these two companies, offering valuable insights into the evolving dynamics of the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025